Enhancing the Bioavailability of Cannabinoids
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Plandaí Biotechnology has recently been discussing opportunities in the cannabis space and the company’s efforts to develop the first and only full-profile, non-psychoactive cannabis extract.
Callum Cottrell-Duffield, Chief Operating Officer of Plandaí, recently released the following statement, “We are one hundred percent focused on getting a full-profile, non-psychoactive cannabis extract product to market. We believe that with the synergies of the full cannabinoid profile, including the acid precursors of THC and CBD, the extract will yield a finished product with great consumer potential. Prior research has demonstrated that cannabis, in its natural state, does not have psychotropic properties. It is the process of heating and drying cannabis that metabolizes the THC-A and THC-B precursors into psychoactive THC. Our extraction method, which relies on sonoluminescence instead of super-critical extraction, never introduces heat or drying into the process until after the molecules are stabilized. The resulting product should provide the full potential of cannabis, not just CBD, but without the side effects. In addition, we expect that our cannabis extract will demonstrate the same high levels of bioavailability as our other extracts, which have been clinically proven to have 15 times greater absorption in the blood stream over generic extracts. We have the potential to produce an extremely powerful, full-profile, non-psychoactive cannabis product.”
Discussing the medical potential of the product, Mr. Cottrell-Duffield added, “Science is slowly beginning to research and understand the human endo-cannabinoid system. This system helps modulate a variety of functions, including pain, memory, mood, and locomotor activity. It is for this reason, we believe, that ingesting cannabis has been linked to improvements across a variety of neural-related problems such as controlling tremors, epilepsy, depression, and pain. Once we have government approval in South Africa to commence producing our extract, our South African subsidiary plans to immediately establish a controlled-growing and extraction facility. Our extract will then be thoroughly validated with respect to composition, bioavailability and non-psychoactivity.”
Mr. Cottrell-Duffield concluded, “We are convinced that consumers will gladly welcome a highly bioavailable full profile cannabis extract, that doesn’t come with any psychoactive side effects. We believe our extraction technology, in conjunction with our Phytofare Catechin Complex, that has been clinically shown to increase the bioavailability of plant catechins in the blood-stream for more than 24 hours, holds significant promise for a wide variety of consumer based products, especially as the legal and societal barriers to the acceptance of cannabis continue to fall by the wayside worldwide.”